LEI105 is a potent, highly selective and reversible dual diacylglycerol lipase (DAGL)-alpha/DAGL-beta inhibitor. LEI105 reduces 2-arachidonoylglycerol levels in Neuro2A cells. LEI105 also reduces cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model. LEI105 is promising for research of diseases, such as obesity, related metabolic disorders and neuroinflammation[1].
Molecular Weight:
384.47
CAS Number:
[1800327-36-9]
Formula:
C25H24N2O2
Target:
DAGL
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
